Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Dual BChE/Nrf2 modulator shows benefit in Alzheimer’s models
8+ hour, 11+ min ago (22+ words) BioWorld News Dual BChE/Nrf2 modulator shows benefit in Alzheimer’s models...
Financing at Immitra Bio to advance in vivo gene editing therapies
8+ hour, 11+ min ago (24+ words) BioWorld News Financing at Immitra Bio to advance in vivo gene editing therapies...
M-511-0965 blocks YAP-TEAD4 signaling in TNBC
6+ hour, 51+ min ago (78+ words) In breast cancer, dysregulated Hippo signaling results in activation of the YAP/TAZ-TEAD transcriptional complex, which induces a broad oncogenic transcriptional program. This gene expression network promotes tumor cell proliferation, survival, invasion and metastatic dissemination, while also contributing to resistance…...
Capital remains selective in ‘barbell’ biotech market
1+ day, 6+ hour ago (16+ words) BioWorld News Capital remains selective in ‘barbell’ biotech market...
US-based Axiom plans Hong Kong listing
1+ day, 1+ hour ago (16+ words) BioWorld News US-based Axiom plans Hong Kong listing...
Rinascera launches with two rare genetic skin disease therapies
2+ day, 5+ hour ago (20+ words) BioWorld News Rinascera launches with two rare genetic skin disease therapies...
UK biotech reports record VC funding in Q2 2026
2+ day, 5+ hour ago (80+ words) U.K. biotech has recorded the strongest quarter for venture capital raised in five years, with companies attracting £2.05 billion (US$3.36 billion) in the second quarter (Q2) of 2026. While that figure is dominated by the £1.56 billion series B round raised by Google Deepmind’s AI…...
Capital remains selective in ‘barbell’ biotech market | BioWorld
6+ day, 2+ hour ago (16+ words) Capital remains selective in ‘barbell’ biotech market BioWorld News Capital remains selective in ‘barbell’ biotech market...
Eliane Schutte, CEO, Xeltis
6+ day, 19+ hour ago (57+ words) Xeltis has bagged a CE mark for aXess, its restorative vascular access conduit for hemodialysis. The company believes that the technology could offer hemodialysis patients a more reliable, long-lasting access option that can improve their quality of life while reducing…...
New AR antagonist for mutated prostate cancer disclosed | BioWorld
2+ week, 2+ day ago (18+ words) New AR antagonist for mutated prostate cancer disclosed BioWorld News New AR antagonist for mutated prostate cancer disclosed...